CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL

Overview

This study is designed to test whether CT-2103/carboplatin provides improved overall survival compared to paclitaxel/carboplatin in women with NSCLC who have estradiol levels >30 pg/ml.

Full Title of Study: “Paclitaxel Poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) in Women With Estradiol > 25 pg/mL”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 5, 2010

Interventions

  • Drug: CT-2103/carboplatin
    • CT-2103 (175 mg/m2 10 min IV infusion) and carboplatin (AUC 6, 30 min IV infusion) on day 1 of each 21-day cycle for up to 6 cycles.
  • Drug: paclitaxel/carboplatin
    • Paclitaxel (175 mg/m2, 3 hr IV infusion) and carboplatin (AUC 6) (30 minute IV infusion) on day 1 of each 21-day cycle for up to 6 cycles.

Arms, Groups and Cohorts

  • Experimental: Experimental
  • Active Comparator: Control

Clinical Trial Outcome Measures

Primary Measures

  • Survival
    • Time Frame: up to 3 years post treatment

Secondary Measures

  • progression-free survival, disease control, clinical benefit, response rate, quality of life, and the safety
    • Time Frame: up to 3 years post treatment

Participating in This Clinical Trial

Inclusion Criteria

1. Women with baseline estradiol >25 pg/mL 2. Histologically- or cytologically-confirmed diagnosis of NSCLC. 3. ECOG performance score (PS) of 0, 1, or 2. 4. Patients must meet one of the following criteria have either (1) Recurrent disease following completion of radiation or surgery, (2) Stage IIIB disease and not be a candidate for combined modality therapy (primary radiation therapy or surgery), or (3) Stage IV disease. 5. At least 18 years of age. 6. Adequate bone marrow function 7. Adequate renal function 8. Adequate hepatic function 9. Life expectancy ≥12 weeks Exclusion Criteria:

1. Known hypersensitivity to the excipients or the study drug (either CT-2103, paclitaxel, or carboplatin that the patient will receive. 2. Evidence of small cell carcinoma, carcinoid, or mixed small cell/non-small cell histology. 3. Weight loss >10% in previous 6 months 4. LDH > 2.5X IULN 5. Both LDH > 1.5X IULN and ≥ 5% weight loss in previous 6 months 6. BMI >35 7. Any prior systemic chemotherapy for the treatment of lung cancer. This includes systemic radiosensitizers used to treat brain metastases and any biologic agent. 8. Local palliative radiotherapy < 7 days before randomization. 9. Radiation with curative intent < 30 days before randomization. 10. Concurrent primary malignancies except for carcinoma in situ or non-melanoma skin cancer. 11. Grade 2 or greater neuropathy. 12. Evidence of significant unstable neurological symptoms within the 4 weeks before study randomization. 13. Clinically significant active infection for which active therapy is underway. 14. Investigational therapy within 4 weeks before randomization, unless local requirements are more stringent. 15. Unstable medical conditions including unstable angina or myocardial infarction within the past 6 months before randomization. 16. Pregnant women or nursing mothers.

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • CTI BioPharma
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jack W. Singer, M.D., Study Director, CTI BioPharma

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.